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KEY POINTS: 78 
1. Ex vivo drug profiling captures disease-relevant features and relevant sensitivity to 79 
therapeutic agents in ALL 80 
2.  A subset of resistant T-ALL without mutations in ABL1 is highly responsive to 81 
dasatinib providing a rationale for drug repurposing  82 
 83 
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ABSTRACT 84 
Drug sensitivity and resistance testing on diagnostic leukemia samples should provide 85 
important functional information to guide actionable target and biomarker discovery. We 86 
provide proof of concept data by profiling 60 drugs on 68 acute lymphoblastic leukemia (ALL) 87 
samples mostly from resistant disease in co-cultures on bone marrow stromal cells. Patient-88 
derived xenografts retained the original pattern of mutations found in the matched patient 89 
material. Stromal co-culture did not prevent leukemia cell cycle activity, while a specific 90 
sensitivity profile to cell cycle related drugs identified samples with higher cell proliferation 91 
both in vitro and in vivo as leukemia xenografts. In cases with refractory relapses, individual 92 
patterns of marked drug resistance, but also exceptional responses to new agents of 93 
immediate clinical relevance were detected. The BCL2-inhibitor venetoclax was highly active 94 
below 10 nM in BCP-ALL subsets including MLL-AF4 and TCF3-HLF ALL, and in some T-95 
ALLs, predicting in vivo activity as a single agent and in combination with dexamethasone 96 
and vincristine. Unexpected sensitivity to dasatinib with IC50 values below 20 nM was 97 
detected in two independent T-ALL cohorts, which correlated with similar cytotoxic activity of 98 
the SRC Inhibitor KX2-391 and inhibition of SRC phosphorylation. A patient with refractory T-99 
ALL was treated with dasatinib based on drug profiling information and achieved a five-100 
month remission. Thus, drug profiling captures disease-relevant features and unexpected 101 
sensitivity to relevant drugs, which warrants further exploration of this functional assay in the 102 
context of clinical trials in order to develop drug repurposing strategies for patients with 103 
urgent medical needs.  104 
 105 
INTRODUCTION 106 
The treatment of relapsed and refractory ALL remains challenging1. Progress in ALL 107 
genomics2 provides unprecedented insight into potentially actionable targets, such as 108 
activating mutations in tyrosine kinases3, RAS4 or IL7R5. Recurrent features such as MLL-109 
AF4 rearrangements, the TCF3-HLF fusion6, or hypodiploid karyotypes4 define rare 110 
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subgroups with highly resistant disease. However, a majority of patients who may benefit 111 
from innovative therapies are still identified based on the persistence of minimal residual 112 
disease (MRD)1,7,8 or remission-induction therapy failure9.  113 
Large integrative studies on cell line panels illustrate the difficulty of extrapolating drug 114 
responses based on genomic data10,11, even when indicative lesions in druggable pathways 115 
occur. Moreover, such alterations may be over- or underrepresented in cell lines, whereas 116 
patient-derived xenografts (PDX) appear to reproduce the  genetic driver mutation landscape 117 
in leukemia more closely12-14. To obtain insight into inter-patient drug response heterogeneity, 118 
we developed an in vitro platform directly using patient-derived leukemia cells. We 119 
hypothesized that drug response profiling of ALL even without a priori information on genetic 120 
lesions or activated pathways will detect sensitivity that may otherwise be overlooked. This 121 
approach will complement in vivo PDX models, which have obvious limitations in compound 122 
coverage and flexibility15. Drug sensitivity testing revealed individual drug response 123 
phenotypes in AML16 and identified new strategies to bypass tyrosine kinase inhibitor (TKI) 124 
resistance in patients with deleterious BCR-ABL mutations17. Conversely, characteristic 125 
tyrosine kinase mutations could be predicted based on drug activity18. Drug activity patterns 126 
can also identify an ALL subtype with  tonic pre-BCR signalling19.  127 
To establish a drug profiling platform, we took advantage of PDX from clinically relevant ALL 128 
subgroups20-24 and based on previous reports16,18,21-23,25,26, adapted a serum free ALL co-129 
culture system on h-TERT immortalized human bone marrow-derived mesenchymal stromal 130 
cells (MSC)27,28 to an automated microscopic image readout for drug testing. This population-131 
based approach reveals relevant activity clusters of therapeutic agents, identifying actionable 132 
targets that have not yet been exploited in conventional ALL treatment.  133 
MATERIALS AND METHODS 134 
Human samples. Primary human ALL cells were recovered from cryopreserved bone 135 
marrow aspirates of patients enrolled in the ALL-BFM 2000, 2009 and ALL-REZ-BFM 2002 136 
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studies. Informed consent was given in accordance with the Declaration of Helsinki and the 137 
ethics commission of the Kanton Zurich (approval number 2014-0383). Samples were 138 
classified as standard-risk (SR), medium-risk (MR), high-risk (HR), or very high-risk (VHR) 139 
according to the ALL-BFM 2000 stratification22, or as relapse (R) and refractory relapse (RR). 140 
Patients from a second cohort consented to protocols reviewed by the Institutional Review 141 
Boards at Oregon Health & Science University and UT-Southwestern. 142 
Xenograft model. Patient derived xenografts (PDX) were generated as described23 by 143 
intrafemoral injection of 1x105 to 5x106 viable primary ALL cells in NSG mice. Leukemia 144 
progression was monitored in the peripheral blood by flow cytometry using anti-mCD45, anti-145 
hCD45, anti-hCD19 or anti-hCD7 antibodies. Xenograft identity was verified by DNA 146 
fingerprinting using the commercial AmpFlSTR® NGM SElectT kit.  147 
Genomic characterization of leukemia samples.  148 
Primary patient material and matched xenografts were analysed by targeted sequencing and 149 
multiplex ligation-dependent probe amplification (MLPA). In 19 BCP-ALL, cases without an 150 
established abnormality (B-other)29 or targetable kinase-activating lesions3, fluorescence in-151 
situ hybridization (FISH) was performed (Probes from Cytocell, Cambridge, UK). Detailed 152 
protocols are in the supplementary methods section.  153 
In vitro drug profiling platform. Drug responses were assessed in ALL cell co-cultures 154 
on hTERT-immortalized primary bone marrow mesenchymal stromal cells (MSC)20 as 155 
described22 in 384 well plates (Greiner, REF781090). 2.5x103 MSC cells/well were 156 
plated in 30µL AIM-V® medium 24h before adding 2-3x104 ALL cells in 27.5µL medium 157 
recovered from cryopreserved samples. Compounds were reconstituted in DMSO 158 
(10mM stock concentrations) and stored at -80°C. Serially-diluted drugs were prepared 159 
using epMotion 5070 and Tecan D300 robots. An independent T-ALL cohort was tested 160 
as described in18. 161 
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Drug response quantification and statistical analysis. We used a fitting routine based on 162 
the four-parameter log-logistic function (R package drc, version 2.3-96) on data normalized 163 
against DMSO-treated samples. Outliers were detected and removed prior to curve fitting by 164 
detecting local slope changes with a linear fit. Non-convergent cases were identified based 165 
on linear fit parameters. R codes are available under 166 
https://github.com/pampernickel/drTools. Hierarchical clustering was performed to group 167 
patients according to their drug responses (R package gplots). Differential drug responses of 168 
patient groups of interest were evaluated using the non-parametric, Mann-Whitney U-test. 169 
In vivo drug treatment. Venetoclax and combinations: 5-8 mice were transplanted with 170 
1x106 ALL cells i.v. per treatment arm. Randomized cohorts were treated with vehicle, 100 171 
mg/kg/day venetoclax (Activebiochem30) orally, 10.5 mg/kg dexamethasone (Mepha) i.p. bi-172 
weekly and 0.5 mg/kg Vincristine (Teva) i.p. once a week. Cytarabine, docetaxel and 173 
dasatinib: animals (one per condition) were intravenously transplanted with 7x106 ALL cells. 174 
After five days, animals were treated with 50mg/kg cytarabine (Sandoz) i.p. for five days, 175 
5mg/kg docetaxel (Taxotere) i.v. twice or 50mg/kg dasatinib (Selleck, dissolved as 176 
described31) orally for five days. Leukemic burden was determined post-treatment by flow 177 
cytometry. 178 
Cell assays. Viability: Viability in 2.5x104 ALL cells in suspension or co-culture with 2.5x103 179 
MSC cells in AIM-V medium was measured by flow cytometry at 1, 4 and 7 days (7-AAD, 180 
reported as day 4 mean+SD). Proliferation and apoptosis:1x105 ALL cells were seeded with 181 
1x104 MSC. Proliferating and apoptotic cells were labelled using the Click-iT EdU Imaging Kit 182 
and Cell EventTM Caspase-3/7 Green, respectively. Proliferating and non-proliferating groups 183 
were identified with an Expectation-Maximization (EM)-mixture model (R package mixtools). 184 
Intracellular flow cytometry and Western Blot. 10x106 ALL cells were fixed in 2% 185 
paraformaldehyde, permeabilized with ice-cold methanol, and indirectly tagged with FITC-186 
labelled antibodies. For Western blots (Bio-Rad Criterion™) whole-cell extracts from 3-5x106 187 
cells were used. Detailed protocols are in the supplementary methods section. 188 
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 189 
RESULTS 190 
Drug response profiling reveals distinct clusters of activity in ALL 191 
Co-cultures on hTERT-immortalized MSC28 facilitate survival of most B-cell precursor (BCP-) 192 
and T-ALL cells21. This protective effect may even increase the stringency of drug testing32. 193 
We tested 60 preclinical and clinical compounds (Table S1) using an imaging-based cell 194 
viability readout21 (Figure 1) on ALL xenografts derived from patients with standard-risk or 195 
high-risk ALL based on MRD persistence, and relapsed and refractory ALL. Patient and PDX 196 
samples were characterized using established diagnostic workflows, including tests for most 197 
recurrent translocations that activate tyrosine kinase pathways (Table S2A and S2B) and by 198 
targeted sequencing of 52 frequently mutated genes in ALL. We retrieved the expected 199 
pattern of mutations (Figure S1, Table S3), with frequent events in KRAS (13/25) and TP53 200 
(10/25), consistent with previous reports33,34. On average, 74% of single nucleotide variants 201 
(SNVs) and insertions/deletions (indels) were conserved between the primary diagnostic 202 
samples and PDX (Figure 1B, Figure S1). Oncogenic translocations were always 203 
maintained. We also included samples from poor- and favourable-risk groups, TCF3-HLF- 204 
and TCF3-PBX1-positive ALL subtypes, for which we recently reported a strong conservation 205 
of the genomic landscape in PDX35. 206 
To evaluate the potential of this ex-vivo platform, we profiled 24 T-ALL and 44 BCP-ALL 207 
PDX, derived from pre-treatment diagnostic samples (ALL-BFM-2000 study36, Figure 2). For 208 
each drug, we used eight doses, optimized from an initial five-point screen (Table S4). None 209 
of the tested compounds affected MSC viability at concentrations lethal to ALL cells, 210 
indicating selective drug activity (Figure 2). Unsupervised clustering of drug responses 211 
(shown here as IC50 values) identified various patterns of response. Compounds including 212 
anthracyclines, the BH3 mimetic navitoclax (ABT-263) and the proteasome inhibitor 213 
bortezomib were effective at low (IC50<10nM) and narrow IC50 range in most cases (cluster 214 
A). A second group of agents including the BCL2-specific BH3 mimetic venetoclax30, tyrosine 215 
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kinase inhibitors and conventional cytotoxic agents such as glucocorticoids, topoisomerase 216 
inhibitors and nucleotide analogues (gemcitabine, cytarabine) showed responses distributed 217 
over a wider concentration range, with high activity in the nanomolar range in some cases 218 
and low activity in others (clusters B, C and E). Venetoclax (Cluster C) was generally more 219 
active in BCP-ALL, but showed similar activity in a T-ALL subset. In cluster E, we identified 220 
two groups of agents, whose separation was driven by differences in response to 221 
antimetabolites (cytarabine, gemcitabine), antimitotic drugs (vincristine, docetaxel), the 222 
aurora kinase inhibitors AT9283 and barasertib and the Polo-like kinase inhibitor BI-2536. 223 
Finally, very strong sensitivity was detected in a few ALL cases for drugs that were otherwise 224 
generally not active in ALL on this platform (cluster G). These included SMAC mimetics (e.g. 225 
LCL161), an observation which led us to show that a BCP-ALL subset was extremely 226 
responsive to SMAC mimetics through RIP1 kinase-dependent necroptosis and apoptosis37. 227 
The ABL/SRC inhibitor dasatinib is also highly active in a T-ALL subset, which we discuss 228 
below. High peak plasma concentrations (Cmax) were reported for most clinical compounds 229 
in our panel (Figure S2), suggesting that effective concentrations may be achieved in vivo. 230 
Our platform provides reproducible drug activity profiles that identify functional phenotypes 231 
and give new insights for therapeutic targeting. No correlations between drug responses and 232 
genetic lesions were found (Table S5). 233 
Drug profiling captures leukemia intrinsic differences in cell proliferation and survival 234 
While most ALL samples tested in co-culture survive on MSC, we noticed relative cell 235 
survival heterogeneity, suggesting differences in cell proliferation and spontaneous cell death 236 
rates across samples (Figure 3A). We did not detect ALL migration beneath stromal cells 237 
(pseudoemperipolesis) or cobblestone structure-like formation26 that could interfere with 238 
microscopy readouts. Median cell viability on MSCs was 69% of seeded cells for BCP-ALL 239 
and 94% for T-ALL, compared to 1.2% and 45.5% in monoculture after 96 hours. A high rate 240 
of survival on this platform (viability of >70% at day 3 compared to day 0) correlated with a 241 
higher ratio (r>1) of cells in S-phase versus apoptotic cells (Figure 3A). To determine 242 
whether these differences are due to stromal co-culture effects or intrinsic features of ALL 243 
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cells, we compared leukemia proliferation and drug sensitivity patterns ex vivo and in vivo in 244 
leukemia xenografts. Marked differences in sensitivity were detected in both BCP- and T-ALL 245 
for drugs whose mechanisms of action require active cycling (Figure 2 cluster E, Figure S3), 246 
including mitotic spindle formation inhibitors, DNA synthesis, cell cycle and mitosis regulatory 247 
kinases. We used a mixture model fit to distinguish high- (>40% of cells in S-phase) from 248 
low- (<40% of cells in S-phase) proliferating ALL cases. ALL samples with high proliferative 249 
activity in vitro engrafted significantly faster (p-value=0.0008) than samples with low 250 
proliferative activity (Figure 3B). As expected, drugs with the highest differential activity in 251 
high- and low-proliferating samples inhibit targets involved in cell cycle control (Figure S4). 252 
Most importantly, samples with rapid engraftment kinetics (Figure 3B) were more sensitive to 253 
cytarabine and docetaxel ex vivo (Figure 3C), which correlates with stronger anti-leukemic 254 
effects in vivo (Figure 3D). Thus, the ex vivo co-culture model captures leukemia-specific 255 
characteristics with respect to cell cycle activity, which are preserved in vivo in the leukemia 256 
xenograft model and are not caused by the co-culture conditions. 257 
As other groups opted for systems based on monocultures, we compared our co-culture data 258 
to a readout in serum supplemented liquid leukemia cultures 18. Selecting 8 BCP-ALL and 19 259 
T-ALL samples, we confirmed improved survival of most of these samples on MSC 260 
compared to cell suspension cultures (Figure S5A-B). While IC50 values from co-culture 261 
and monoculture were significantly correlated for 22 drugs tested under both conditions 262 
(Spearman ρ=0.64, p-value <2.2e-16), there were several discrepancies in drugs of interest. 263 
We observed a significant correlation of drug activity in co-cultures with in-vivo drug 264 
responses (Figure S5D-F), most evident for venetoclax (Figure S5D), docetaxel and 265 
dasatinib, and to a lesser extent for cytarabine (Figure S5E). In contrast, drug activity data 266 
obtained from liquid monocultures only showed a predictive trend for cytarabine, but not for 267 
the other agents tested (Figure S5F). These observations support the potential of our 268 
system for the identification of relevant vulnerabilities in a clinical setting.  269 
11 
 
Drug profiling reveals individual patterns of drug sensitivity and resistance in relapsed 270 
and refractory ALL  271 
Drug profiling may convey relevant information to select new agents for salvage therapy in 272 
patients with highly resistant disease. To compare the activity of different substances in 273 
different patients, it is important to evaluate drug activity in a single case against the full 274 
response range obtained on the same platform for other leukemia cases, including clinically 275 
relevant subsets. We profiled PDX samples of twelve patients with relapsed ALL refractory to 276 
salvage therapy (refractory relapse, RR), who did not achieve a second or third remission 277 
required for inclusion in early clinical trials (Figure 4A), as well as primary leukemia cells 278 
from five patients with refractory disease in real time prospectively (Figure 4B, Table 1). 279 
Figure 4 shows IC50 values for a selection of therapeutic agents in samples of interest 280 
against those obtained for all other samples on our platform (grey). RR ALL samples were 281 
generally more resistant to agents used for induction in ALL such as dexamethasone (10/12 282 
cases), cytarabine (9/12 cases) and doxorubicin (9/12 cases), compared to other diagnostic 283 
and relapse ALL cases (Figure 4A). In contrast, individual samples were highly sensitive to 284 
dexamethasone, idarubicin and mitoxantrone, which are included in the standard of care for 285 
relapsed ALL38, and to new agents from different classes, such as venetoclax, dasatinib, 286 
bortezomib, nutlin, JQ1 and panobinostat. Again, we noticed unexpected responses in a few 287 
cases to venetoclax and dasatinib, which we discuss in the next sections. Additionally, 288 
sensitivity patterns could be associated with cytogenetic groups. For example, MLL-AF4 ALL 289 
cases were sensitive to PI3K/mTOR/AKT or HSP90 inhibitors, consistent with previous 290 
reports39 (Figure S6). 291 
To assess the feasibility of our approach in the clinical setting, we tested five cases with 292 
highly refractory ALL at the time of relapse (Figure 4B). Results could be obtained within five 293 
days. These cases did not respond to standard of care drugs on the platform 294 
(dexamethasone, vincristine, doxorubicin or mitoxantrone), but were individually sensitive to 295 
venetoclax (Patients 1, 2, 3) and panobinostat (Patient 5). Thus, drug profiling may provide 296 
important information when exploring options for patients with resistant disease.  297 
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The response to venetoclax ex vivo correlates with strong in vivo anti-leukemic 298 
activity as single agent and in combination 299 
Given the strong in vitro activity of venetoclax across various ALL subtypes, including a 300 
subset of T-ALLs, BCP-ALLs, TCF3-HLF ALL and all MLL-AF4 ALL cases, we tested 301 
venetoclax (n=7) in vivo in the xenograft model (Figure 5A). Several T-ALL cases responded 302 
to venetoclax in vitro with IC50 values in the nanomolar range (Figure 5A), consistent with 303 
reports describing activity in early thymic precursor ALL and T-ALL40-42. These results were 304 
verified by flow cytometry using 7-AAD staining to quantify cell death (Figure S7). As 305 
expected, the response to oral administration of venetoclax in vivo correlated with in vitro 306 
activity for three T-ALL patients with strong, intermediate and low venetoclax sensitivity. 307 
Single agent venetoclax treatment delayed leukemia progression significantly in the case 308 
with strong in vitro sensitivity (HR=20, IC50 <1nM and low Emax, treated vs. untreated, 309 
p<0.005) compared to cases with low IC50 (<100nM) but higher Emax (HR=0.07, treated vs. 310 
untreated, p<0.005) or high IC50 (>1μM). Additionally, complete response was detected 311 
when treating the T-VHR-03 case in mice with high leukemia burden (75% engraftment, 312 
Figure S8). We recently reported similar venetoclax efficacy in three TCF3-HLF ALL cases 313 
in vivo35; comparable correlations were obtained in two cases with TCF3-HLF and with MLL-314 
rearranged ALL (Figure 5A). For all tested cases, venetoclax-induced delays in in vivo 315 
leukemia progression correlated with in vitro responses (Figure 5B, Spearman ρ=-0.86, p-316 
value<0.05).  317 
As with most chemotherapeutic agents, single agent venetoclax therapy is unlikely to be 318 
effective. Currently, most investigational agents will be tested in combination with a standard 319 
of care anti-leukemic regimen, including two to four drugs such as vincristine, 320 
dexamethasone, asparaginase and an anthracycline typically used for reinduction 321 
chemotherapy at relapse38. We detected synergy in vitro using co-titration experiments, but 322 
this assay is challenging when assessing a drug with such strong in vitro activity as 323 
venetoclax43 (Figure S9, Table S4). As it is impossible to provide supportive care to mice 324 
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after myelotoxic chemotherapy in vivo, we next tested the combination of venetoclax, 325 
dexamethasone and vincristine without anthracyclines (Figure 5A). Venetoclax or 326 
chemotherapy alone delayed leukemia progression for TCF3-HLF and MLL-AF4 rearranged 327 
cases (HR=5-22, p-value<0.005). The three-drug combination prevented leukemia 328 
progression for more than 300 days in two TCF3-HLF samples and in three out of five MLL-329 
AF4 ALL samples. Leukemia progression was significantly delayed in remaining samples.  330 
The identification of response-predictive biomarkers, in addition to drug profiling, is important 331 
for the clinical development of BH3 mimetics. The BCL2:BCL-XL and BCL2:MCL1 ratios 332 
were suggested as biomarkers for venetoclax sensitivity in ALL44 and in multiple myeloma45, 333 
respectively. We determined levels of BCL2-family members by intracellular flow cytometry 334 
and Western blotting (Figure 5C, Figure S10). In vitro response to venetoclax neither 335 
correlated with BCL2-family protein expression levels nor BCL2:MCL1 or BCL2:BCL-XL 336 
ratios in 36 BCP-ALL and T-ALL samples tested by flow cytometry (Figure 5C, Figure S11). 337 
It will be important to perform further BH3 profiling in parallel with drug response profiling in 338 
clinical trials to establish predictive biomarkers.  339 
Drug profiling identifies a subset within T-ALL highly responsive to dasatinib  340 
We detected unexpected responses to the ABL1/SRC inhibitor dasatinib (IC50<100nM) in 341 
twelve (30%) T-ALL cases without the typical ABL1 kinase translocation (Figure 6A). 342 
Importantly, these responses were detected in both diagnostic and relapse samples from 343 
high-risk patients by MRD. Moreover, the IC50 for dasatinib in these cases was at least a 344 
tenfold lower than in any of the best BCP-ALL responders tested. These included five ALL 345 
cases with rearranged TCF3-PBX1, recently linked to active BCR signalling19,46, that were 346 
sensitive to dasatinib but not imatinib (Figure 6A). No known recurrent genetic abnormality 347 
could be linked to this phenotype (Table S3). We found neither recurrent mutations nor gene 348 
fusions by exome and transcriptome sequencing that associated with dasatinib sensitivity in 349 
T-ALL (Table S6). RNASeq also indicated that dasatinib sensitive case had low FYN, but 350 
high SRC expression (Figure S12). Given that the dasatinib response did not correlate with 351 
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the response to other BCR-ABL inhibitors, we hypothesized that dasatinib acts via SRC 352 
inhibition. By phospho-flow cytometry, we detected higher levels of activated, phosphorylated 353 
SRC in dasatinib-sensitive samples (Figure 6B); SRC phosphorylation was abrogated after 354 
exposure to dasatinib. The SRC inhibitor KX2-391, which inhibits SRC at nanomolar 355 
concentrations47, induced cell death in dasatinib-sensitive T-ALL cases at concentrations 356 
below 100nM (Figure 6C), supporting the relevance of the SRC pathway in this T-ALL 357 
subset. Apart from KX2-391, dasatinib response also correlated with responses to other RTK 358 
inhibitors (e.g. midostaurin, crenolinib, adj. p-value<0.005; Figure S13), consistent with the 359 
central role of SRC in receptor tyrosine kinase (RTK) signalling48. Importantly, in vitro 360 
response to dasatinib correlated with anti-leukemic activity in vivo in T-ALL xenografts 361 
(Figure 6D).  362 
To validate our observations, we checked the drug sensitivity of 33 adult and pediatric T-ALL 363 
patients obtained on a liquid monoculture platform18. Remarkably, 4/33 responded to 364 
dasatinib with IC50 < 10nM (Figure 6E), and 9/33 with 10 nM < IC50 < 100nM. One of these 365 
samples was from an adult male patient with refractory T-ALL with mediastinal and 366 
abdominal lymph node involvement after 8 cycles of hyper CVAD chemotherapy, allogeneic 367 
stem cell transplantation, and relapse treatment with nelarabine, mitoxantrone and 368 
cytarabine. Based on these results, dasatinib (140 mg/day) was initiated, first in combination 369 
with pegylated asparaginase, which was interrupted after one dose due to intolerance. 370 
Dasatinib monotherapy was continued and interval resolution of all lesions was evidenced on 371 
a repeat PET/CT two month after initiation of dasatinib (Figure 6F). In total, the disease 372 
could be controlled over 5 months. While the short exposure to asparaginase may have 373 
contributed to this response, the disease control with dasatinib monotherapy over several 374 
months is indicative of clinical activity. These results confirm that a subset of drug resistant 375 
and relapsed T-ALL can be identified by drug profiling to be particularly sensitive to dasatinib, 376 
and warrants further exploration of underlying molecular mechanisms. Given the experience 377 
with established combinations of dasatinib with chemotherapy for the treatment of BCR-ABL 378 
positive ALL49, our data provide a strong rationale for drug repurposing based on drug 379 
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profiling results for selected patients with resistant T-ALL in pediatric and adult patient 380 
populations.  381 
 382 
 383 
DISCUSSION 384 
Here we provide compelling evidence that informative and reproducible differences in drug 385 
response profiles can be detected in patient groups of interest while simultaneously revealing 386 
patient-to-patient response variations. Heterogeneous and strong activity was found for 387 
different classes of agents in refractory ALL cases. We did not observe any correlations 388 
between drug response phenotypes and somatic mutations, which may be partly due to the 389 
limited size of our cohort; multivariate analyses based on whole genome or exome 390 
sequencing results on a larger cohort would be of interest in the future to establish 391 
correlations definitively. However, our results, which indicate that it will be challenging to infer 392 
drug activity solely based on genomic data, are consistent with reports in adult hematologic 393 
malignancies16,18.  394 
As a basis for standardization, we opted for co-culture on human MSC27,28, which efficiently 395 
supported most of the primary ALL samples that we tested in serum-free conditions. Our 396 
assay provides better ALL cell survival and stronger correlation with in-vivo drug activity in 397 
PDX models compared to monocultures (Figure S5). This model also increases the 398 
possibilities for multidimensional expansion. Effects can be analysed not only on the target 399 
leukemia cells, but also on non-hematopoietic microenvironmental cells, and use of 400 
additional markers that indicate for instance metabolic states, distinct differentiation 401 
processes or signalling activity could be envisaged. The fact that we detect subsets with 402 
more proliferative activity both in vitro and in vivo based on drug profiling indicates that 403 
important leukemia-intrinsic features are maintained and captured under the in vitro cell 404 
culture conditions. We and others16,18 have demonstrated the use of drug profiling for the 405 
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identification of responsive phenotypes to new therapeutic agents. We have identified 406 
recurrent ALL cases highly sensitive to triggering RIP1-dependent cell death with SMAC 407 
mimetics37, or to BCL2 inhibition in BCP-ALL subsets, including TCF3-HLF ALL35 and T-ALL 408 
subsets. Moreover, we discovered a subgroup in T-ALL that is highly sensitive to dasatinib, 409 
which should be further evaluated first in patients with highly resistant and refractory disease.  410 
Drug response profiling may contribute to defining cohorts that may benefit from new agents. 411 
The profiles that we detected for venetoclax30, which was recently approved for CLL 412 
treatment, illustrate the type of information that could be used to improve patient selection in 413 
early clinical trials. We show that a relatively large proportion of BCP-ALL cases may 414 
respond to venetoclax, including very high-risk subtypes such as TCF3-HLF35 and MLL-AF4 415 
positive ALL. Our findings are confirmed independently by others, showing strong venetoclax 416 
activity in MLL-rearranged ALL50. Supportive information using other biomarkers would be 417 
desirable, also to monitor response in clinical trials. The BCL2:BCL-XL expression ratio was 418 
proposed as a predictive biomarker for venetoclax response44, but our results and other 419 
data50 suggest that this approach may not detect all cases. BH3 profiling using synthetic 420 
peptides instead of targeted small molecule drugs44,51,52 may provide complementary 421 
information, as evaluated in a phase II study assessing venetoclax monotherapy in patients 422 
with refractory/relapsed AML 53. We propose that in vitro drug profiling should be 423 
incorporated in upcoming clinical trials, for example for venetoclax, in order to determine its 424 
predictive potential.  425 
New treatment options are urgently needed for relapsed T-ALL1. We discovered a T-ALL 426 
subset highly sensitive to dasatinib. We also show good response to this tyrosine kinase 427 
inhibitor in a patient with previously refractory T-ALL whose treatment was designed based 428 
on drug profiling data. A patient with NUP1-ABL1 positive T-ALL was also reported to 429 
respond to dasatinib-based therapy54, but none of the cases with high dasatinib sensitivity 430 
were NUP1-ABL1 positive in our series. We did not identify activating mutations that may 431 
directly explain dasatinib sensitivity, indicating that the underlying mechanisms may occur at 432 
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a different level, which will motivate follow-up studies. Given that dasatinib combinations with 433 
ALL standard of care chemotherapy49 and a pediatric dose55 are established, its inclusion in 434 
chemotherapy for patients with resistant T-ALL displaying a dasatinib-responsive phenotype 435 
should be evaluated. Taken together, we demonstrate that in vitro drug profiling captures 436 
functional information of clinical importance and reveals new biological entities in ALL. Given 437 
the growing interest of clinicians in this approach, prospective evaluation is warranted to 438 
establish its value for more precise therapeutic agent selection for patients with resistant 439 
disease. 440 
18 
 
 441 
ACKNOWLEDGMENTS 442 
This work was supported by the Cancer League of the Canton of Zurich, the Empiris 443 
foundation, the foundation “Kinderkrebsforschung Schweiz”, the Sassella foundation, the 444 
“Stiftung für Krebsbekämpfung”, the Swiss National Science Foundation (310030-133108), 445 
the Fondation Panacee, the clinical research focus program “Human Hemato-Lymphatic 446 
Diseases” of the University of Zurich, the German Childhood Cancer Foundation and the 447 
German Cancer Consortium. P.H. acknowledges support from the Hungarian National Brain 448 
Research Program (MTA-SE-NAP B-BIOMAG) and the Finnish TEKES FiDiPro Fellow Grant 449 
40294/13. J.W.T. is supported by The Leukemia & Lymphoma Society, the V Foundation for 450 
Cancer Research, the Gabrielle’s Angel Foundation for Cancer Research, and the National 451 
Cancer Institute (5R00CA151457-04; 1R01CA183947-01). This research received funding 452 
from the European Union’s Seventh Framework Programme for research, technological 453 
development, and demonstration (Grant agreement no. 278514 - IntReALL). V.S. is a 454 
Wellcome-DBT Margdarshi Fellow. M.P.D. is a SystemsX fellow. M.P.D. wishes to thank Dr. 455 
Edoardo Missiaglia for helpful discussions. 456 
 457 
AUTHORSHIP CONTRIBUTIONS 458 
J.-P.B., B.C.B., V.F., M.P.D., A.R. jointly designed the project. J.-P.B., B.C.B., J.W.T., V.F., 459 
A.R., S.H.D. designed experiments. V.F., A.R., J.T., J.K., P.R.-P., P.V., O.P., S.J., B.M., 460 
S.H., J.W.T., S.E., S.H.D. performed experiments. G.C., M.Sc., M.St., M.P.D., T.R., P.V., 461 
M.D., A.E.K., M.U.M., A.v.S., C.E., B.H.C., T.J.B., R.H.C., S.U., P.B., O.R.B., E.D.-F., M.L.L., 462 
E.D.-F., J.T., R.M., V.S., J.A.I., T.R., T.B., R.H.C., S.D. provided reagents, analysis tools, 463 
samples and clinical data. M.P.D., V.F., A.R., P.R.-R., J.K., J.W.T., O.P. S.J. S.H.D., 464 
analysed data and prepared tables and figures. J.-P.B., B.C.B. supervised research. J.-P.B., 465 
B.C.B., M.P.D., V.F. wrote the manuscript. All authors critically reviewed the manuscript for 466 
its content.  467 
 468 
19 
 
CONFLICT OF INTEREST DISCLOSURES 469 
T.R. is a full-time employee of Novartis Pharma AG. The remaining authors declare no 470 
competing financial interests. 471 
 472 
The online version of the article contains a data supplement. 473 
20 
 
 474 
References 475 
1. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood 476 
acute lymphoblastic leukemia. Blood. 2012;120(14):2807-2816. 477 
2. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013. 478 
3. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-479 
like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015. 480 
4. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute 481 
lymphoblastic leukemia. Nature genetics. 2013;45(3):242-252. 482 
5. Shochat C, Tal N, Bandapalli OR, et al. Gain-of-function mutations in interleukin-7 483 
receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 484 
2011;208(5):901-908. 485 
6. Hunger SP, Devaraj PE, Foroni L, Secker-Walker LM, Cleary ML. Two types of 486 
genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. Blood. 487 
1994;83(10):2970-2977. 488 
7. Eckert C, Hagedorn N, Sramkova L, et al. Monitoring minimal residual disease in 489 
children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of 490 
early and late assessment. Leukemia. 2015;29(8):1648-1655. 491 
8. Bader P, Kreyenberg H, von Stackelberg A, et al. Monitoring of Minimal Residual 492 
Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute 493 
Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the 494 
ALL-BFM-SCT 2003 Trial. J Clin Oncol. 2015. 495 
9. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood 496 
acute lymphoblastic leukemia. N Engl J Med. 2012;366(15):1371-1381. 497 
10. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic 498 
markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570-575. 499 
11. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia 500 
enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607. 501 
12. Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived 502 
tumor xenografts to predict clinical trial drug response. Nat Med. 2015;advance online 503 
publication. 504 
13. Wang K, Sanchez-Martin M, Wang X, et al. Patient-derived xenotransplants can 505 
recapitulate the genetic driver landscape of acute leukemias. Leukemia. 2016. 506 
14. Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of 507 
Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 508 
2016;29(4):574-586. 509 
15. Jones L, Carol H, Evans K, et al. A review of new agents evaluated against pediatric 510 
acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia. 511 
2016;30(11):2133-2141. 512 
16. Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to 513 
tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 514 
2013;3(12):1416-1429. 515 
17. Pemovska T, Johnson E, Kontro M, et al. Axitinib effectively inhibits BCR-516 
ABL1(T315I) with a distinct binding conformation. Nature. 2015;519(7541):102-105. 517 
18. Tyner JW, Yang WF, Bankhead A, 3rd, et al. Kinase pathway dependence in primary 518 
human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73(1):285-296. 519 
19. Geng H, Hurtz C, Lenz KB, et al. Self-Enforcing Feedback Activation between BCL6 520 
and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic 521 
Leukemia. Cancer Cell. 2015;27(3):409-425. 522 
21 
 
20. Mihara K, Imai C, Coustan-Smith E, et al. Development and functional 523 
characterization of human bone marrow mesenchymal cells immortalized by enforced 524 
expression of telomerase. Br J Haematol. 2003;120(5):846-849. 525 
21. Boutter J, Huang Y, Marovca B, et al. Image-based RNA interference screening 526 
reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine 527 
support. Oncotarget. 2014;5(22):11501-11512. 528 
22. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent 529 
necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome 530 
glucocorticoid resistance. J Clin Invest. 2010;120(4):1310-1323. 531 
23. Schmitz M, Breithaupt P, Scheidegger N, et al. Xenografts of highly resistant 532 
leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood. 533 
2011;118(7):1854-1864. 534 
24. Mirkowska P, Hofmann A, Sedek L, et al. Leukemia surfaceome analysis reveals new 535 
disease-associated features. Blood. 2013;121(25):e149-159. 536 
25. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on 537 
prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic 538 
leukemia. J Clin Oncol. 2003;21(17):3262-3268. 539 
26. Hartwell KA, Miller PG, Mukherjee S, et al. Niche-based screening identifies small-540 
molecule inhibitors of leukemia stem cells. Nat Chem Biol. 2013;9(12):840-848. 541 
27. Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-542 
derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. 543 
Blood. 1992;79(9):2370-2377. 544 
28. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate 545 
the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 546 
2007;117(4):1049-1057. 547 
29. Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-548 
cell precursor acute lymphoblastic leukemia. Haematologica. 2016;101(4):407-416. 549 
30. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 550 
inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208. 551 
31. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and 552 
pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin 553 
Cancer Res. 2006;12(23):7180-7186. 554 
32. McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in 555 
modifying drug response: challenges and opportunities. Nat Rev Drug Discov. 556 
2013;12(3):217-228. 557 
33. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed 558 
childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 559 
2014;124(23):3420-3430. 560 
34. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene 561 
predict nonresponse to treatment and poor outcome in first relapse of childhood acute 562 
lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185-3193. 563 
35. Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-564 
HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and 565 
therapeutic options. Nat Genet. 2015;47(9):1020-1029. 566 
36. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment 567 
redefines all prognostic factors in children and adolescents with B-cell precursor acute 568 
lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 569 
2010;115(16):3206-3214. 570 
37. McComb S, Aguade-Gorgorio J, Harder L, et al. Activation of concurrent apoptosis 571 
and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Sci 572 
Transl Med. 2016;8(339):339ra370. 573 
22 
 
38. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children 574 
with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. 575 
Lancet. 2010;376(9757):2009-2017. 576 
39. Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood. 2009;113(24):6061-577 
6068. 578 
40. Alford SE, Kothari A, Loeff FC, et al. BH3 inhibitor sensitivity and Bcl-2 dependence 579 
in primary acute lymphoblastic leukemia cells. Cancer Res. 2015. 580 
41. Suryani S, Carol H, Chonghaile TN, et al. Cell and Molecular Determinants of In Vivo 581 
Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia 582 
Xenografts. Clin Cancer Res. 2014. 583 
42. Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a 584 
novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738-585 
3747. 586 
43. Chou TC. Drug combination studies and their synergy quantification using the Chou-587 
Talalay method. Cancer Res. 2010;70(2):440-446. 588 
44. Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute 589 
lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to 590 
ABT-199. Cancer Discov. 2014;4(9):1074-1087. 591 
45. Punnoose EA, Leverson JD, Peale F, et al. Expression Profile of BCL-2, BCL-XL, 592 
and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist 593 
Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016;15(5):1132-1144. 594 
46. Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the Pre-B 595 
cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 596 
2012;22(5):656-667. 597 
47. Fallah-Tafti A, Foroumadi A, Tiwari R, et al. Thiazolyl N-benzyl-substituted 598 
acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med 599 
Chem. 2011;46(10):4853-4858. 600 
48. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted 601 
inhibitors. Nat Rev Cancer. 2005;5(5):341-354. 602 
49. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients 603 
with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 604 
2011;118(25):6521-6528. 605 
50. Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL 606 
xenografts reveal MLLr ALL sensitivity, but overall requirement to target both BCL2 and 607 
BCLXL. Blood. 2016. 608 
51. Ni Chonghaile T, Sarosiek KA, Vo TT, et al. Pretreatment mitochondrial priming 609 
correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129-610 
1133. 611 
52. Montero J, Sarosiek KA, DeAngelo JD, et al. Drug-induced death signaling strategy 612 
rapidly predicts cancer response to chemotherapy. Cell. 2015;160(5):977-989. 613 
53. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of 614 
Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute 615 
Myelogenous Leukemia. Cancer Discov. 2016. 616 
54. Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, et al. Rapid complete 617 
cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-618 
positive T-cell acute lymphoblastic leukemia. Leukemia. 2009;23(3):627-629. 619 
55. Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with 620 
relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the 621 
Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013;31(19):2460-622 
2468. 623 
624 
23 
 
 625 
Table 1. Characteristics of the five patients with refractory disease included in this 626 
study   627 
  628 
FIGURE LEGENDS 629 
 630 
Figure 1. Setup of drug response profiling platform.  631 
Patient material, notably from high-risk cases, including relapse cases and cases with 632 
translocations linked to poor survival, were prioritized for patient-derived xenograft (PDX) and 633 
drug response profiling; PDX stability was evaluated against primary material by comparing 634 
targeted deep-sequenced leukemogenesis markers (A, top panel). Drug profiling was 635 
performed on primary ALL cells in co-culture with mesenchymal bone marrow stroma cells 636 
(MSCs). Automated microscopy-based image analysis was used to quantify living ALL and 637 
generate dose response curves. Imaging results are analysed with a toolkit that performs 638 
dose response normalization, outlier removal, rapid curve fitting, and extraction of response 639 
parameters (IC50, AUC, Emax). Selected single compounds and combinations are validated 640 
in the xenograft model. This platform enables the identification of drug response phenotypes 641 
in individual ALL cases, providing an additional layer of information to facilitate individual 642 
treatment approaches (A, bottom panel). Our PDX model preserves an average of 74% of 643 
the mutations and indels initially detected in patients, making it an ideal source of material for 644 
drug response testing in multi-center, co-clinical settings (B). 645 
 646 
Figure 2. Drug response profiles of BCP-ALL and T-ALL.  647 
Heatmap indicating the response of BCP-ALL (n=44) and T-ALL (n=24) to 60 compounds 648 
and represented by IC50 values. Samples (rows) were ordered according to clinical 649 
classification and compounds (columns) according to activity. Each compound’s IC50 650 
distribution range is shown on the lower panel forming drug clusters: 651 
A: Generally active drugs, mean IC50 values < 10 nM; 652 
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B: Drugs more active in BCP-ALLs than T-ALLs; 653 
C: Generally active drugs, IC50 values < 100 nM; 654 
D: Drugs with variable activity 655 
E: Drugs with activity linked to cycling activity; 656 
F: Generally active drugs, high nanomolar range; 657 
G: Generally inactive drugs, with sporadic exceptions. 658 
On the lower part of the graph heatmap of MSC and drug IC50 distribution box plot are 659 
demonstrated. 660 
 661 
Figure 3. Drug profiling reveals leukemia-intrinsic features.  662 
(A) Co-culturing on MSC supports survival of T-ALL (n=22) and BCP-ALL (n=25). Data at 663 
day 4 are given, normalized to seeded viable cell numbers at day 0 both in monoculture or in 664 
co-culture (left panel). Cell cycle and apoptosis rates of primary T-ALL (n=18) and BCP-ALL 665 
(n=14) cells in co-culture is provided on the right. Samples are ranked from highest (top) to 666 
lowest (bottom) survival. Ratio of cells in S-phase and apoptosis is given on the far right. ****, 667 
p<0.0001 (Paired t-test)  668 
(B) Engraftment kinetics for ALL cases with >40% of cells in S-phase (dotted lines in red) 669 
and with <40% in S-phase (straight blue lines) are given (i.). Time to engraftment with 25% 670 
ALL blasts in the two groups is indicated in the lower panel (ii.). ***, p<0.001 (Two-sided t-671 
test) 672 
(C) In vitro ALL proliferation correlates with drug response to cytarabine (antimetabolite), 673 
docetaxel (antimitotic) and other cell cycle targeting drugs (Figure S4). ALL cells with >40% 674 
of cells in S-phase (red symbols) respond to cytarabine and docetaxel with lower IC50 675 
compared to samples with <40% of cells in S-phase (blue symbols).  676 
(D) Cytarabine and docetaxel response profiles predict in vivo ALL response (N=8).  677 
 678 
Figure 4. Distinct drug activity patterns can be detected for individual samples and 679 
patient groups of interest  680 
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(A) Refractory relapse (RR (PDX), N=12) samples exhibit general resistance to conventional 681 
clinical compounds, but remain sensitive to some experimental drugs.  682 
(C) Primary refractory relapse patients (RR (primary), N=5) tested before last salvage 683 
therapy demonstrate persistent resistance to standard chemotherapy and individual 684 
sensitivity to experimental molecules.  685 
All responses are represented as IC50 (log[nM]) and compared to other diagnostic and 686 
relapse ALL cases depicted in the background. *, p<0.05; **, p<0.005 (Two-sided t-test) 687 
 688 
Figure 5. In vitro sensitivity to the BCL-2 antagonist venetoclax correlates with the 689 
response in leukemia xenografts.  690 
(A) In vitro response to venetoclax for indicated ALL subtypes (black) compared to other ALL 691 
(grey). From top to bottom: mature-T-ALL (N=6), cortical-T-ALL (N=13), pre-T-ALL (N=6), 692 
TCF3-HLF ALL (N=4) and MLL-AF4 ALL (N=3). Cell viability (7-AAD) was measured by flow 693 
cytometry after treatment for 72 hours and normalized against DMSO-treated controls. 694 
Arrows indicate samples whose response had been validated in vivo for venetoclax (top to 695 
bottom: T-VHR-03, T-HR-11 and T-HR-10) or venetoclax in combination with vincristine and 696 
dexamethasone (top to bottom: B-HR-24, B-HR-20, B-HR-26 and B-VHR-07). The left panel 697 
shows the number of leukemia cells compared to mouse lymphocytes over time. The right 698 
panel shows corresponding Kaplan-Meier survival curves (event defined as 25% of mCD45- 699 
hCD45+hCD19+ or hCD7+ leukemia cells detected by flow cytometry).  700 
(B) In vitro response to venetoclax correlates with fold increase of survival comparing 701 
treatment with venetoclax and vehicle (N=7).  702 
(C) BCL2 protein family expression (i.) analysed by flow cytometer in T-ALL (N=16) and 703 
BCP-ALL (N=20). Correlation of BCL2:BCL-XL and BCL2:MCL1 ratio (ii.) with in vitro 704 
venetoclax response. ****, p<0.0001 (two-tailed t test). 705 
 706 
Figure 6. In vitro sensitivity of T-ALL to dasatinib correlates with anti-leukemic efficacy 707 
in the patient.  708 
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(A) Subset of T-ALL cases at diagnosis that relapsed (R) and at relapse are highly sensitive 709 
to dasatinib in vitro.  710 
(B) Dasatinib sensitive T-ALL have higher levels of phosphorylated SRC that decreases after 711 
treatment with 1µM dasatinib for 2h as measured by flow cytometry. ***, p<0.001 (Two-sided 712 
t-test) 713 
(C) Dasatinib response correlates with sensitivity to the SRC inhibitor KX2-391 (N=16).  714 
(D) In vitro captured response correlates with in vivo response to dasatinib (N=10). Indicated 715 
are the % of T-ALL blasts compared to mouse lymphocytes, normalized to vehicle treated 716 
controls.  717 
(E) Sensitivity of adult and pediatric T-ALL cases to dasatinib reveals 40% of cases with IC50 718 
below 100 nM. 719 
(F) Left PET/CT demonstrates significant disease burden throughout the marrow in bilateral 720 
upper and lower extremities, the pelvis, vertebrae, and contiguous nodes within the 721 
mediastinum. Right PET/CT approximately 15 months after the original presentation, shortly 722 
after initiation of dasatanib monotherapy. This image demonstrates complete response with 723 
no signs of marrow or nodal involvement.  724 







